Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial

被引:226
|
作者
Pickard, Robert [1 ]
Starr, Kathryn [2 ]
MacLennan, Graeme [2 ]
Lam, Thomas [3 ]
Thomas, Ruth [2 ]
Burr, Jennifer [5 ]
McPherson, Gladys [2 ]
McDonald, Alison [2 ]
Anson, Kenneth [6 ]
N'Dow, James [3 ]
Burgess, Neil [7 ]
Clark, Terry [8 ]
Kilonzo, Mary [4 ]
Gillies, Katie [2 ]
Shearer, Kirsty [2 ]
Boachie, Charles [2 ]
Cameron, Sarah [2 ]
Norrie, John [2 ]
McClinton, Samuel [3 ,9 ]
机构
[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Univ Aberdeen, Hlth Serv Res Unit, Ctr Healthcare Randomised Trials, Aberdeen, Scotland
[3] Univ Aberdeen, Acad Urol Unit, Aberdeen, Scotland
[4] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland
[5] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland
[6] St Georges Healthcare NHS Trust, London, England
[7] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, Norfolk, England
[8] British Assoc Urol Surg, Sect Endourol, Stone Patient Advisory Grp, London, England
[9] NHS Grampian, Aberdeen Royal Infirm, Aberdeen, Scotland
来源
LANCET | 2015年 / 386卷 / 9991期
关键词
EMERGENCY-DEPARTMENT VISITS; STONE PASSAGE; MANAGEMENT; FACILITATE; DRUG;
D O I
10.1016/S0140-6736(15)60933-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Meta-analyses of previous randomised controlled trials concluded that the smooth muscle relaxant drugs tamsulosin and nifedipine assisted stone passage for people managed expectantly for ureteric colic, but emphasised the need for high-quality trials with wide inclusion criteria. We aimed to fulfil this need by testing effectiveness of these drugs in a standard clinical care setting. Methods For this multicentre, randomised, placebo-controlled trial, we recruited adults (aged 18-65 years) undergoing expectant management for a single ureteric stone identified by CT at 24 UK hospitals. Participants were randomly assigned by a remote randomisation system to tamsulosin 400 mu g, nifedipine 30 mg, or placebo taken daily for up to 4 weeks, using an algorithm with centre, stone size (<= 5 mm or >5 mm), and stone location (upper, mid, or lower ureter) as minimisation covariates. Participants, clinicians, and trial personnel were masked to treatment assignment. The primary outcome was the proportion of participants who did not need further intervention for stone clearance within 4 weeks of randomisation, analysed in a modified intention-to-treat population defined as all eligible patients for whom we had primary outcome data. This trial is registered with the European Clinical Trials Database, EudraCT number 2010-019469-26, and as an International Standard Randomised Controlled Trial, number 69423238. Findings Between Jan 11, 2011, and Dec 20, 2013, we randomly assigned 1167 participants, 1136 (97%) of whom were included in the primary analysis (17 were excluded because of ineligibility and 14 participants were lost to follow-up). 303 (80%) of 379 participants in the placebo group did not need further intervention by 4 weeks, compared with 307 (81%) of 378 in the tamsulosin group (adjusted risk difference 1.3% [95% CI-5.7 to 8.3]; p=0.73) and 304 (80%) of 379 in the nifedipine group (0.5% [-5.6 to 6.5]; p=0.88). No difference was noted between active treatment and placebo (p=0.78), or between tamsulosin and nifedipine (p=0.77). Serious adverse events were reported in three participants in the nifedipine group (one had right loin pain, diarrhoea, and vomiting; one had malaise, headache, and chest pain; and one had severe chest pain, difficulty breathing, and left arm pain) and in one participant in the placebo group (headache, dizziness, lightheadedness, and chronic abdominal pain). Interpretation Tamsulosin 400 mu g and nifedipine 30 mg are not effective at decreasing the need for further treatment to achieve stone clearance in 4 weeks for patients with expectantly managed ureteric colic. Copyright (C) Pickard et al. Open Access article distributed under the terms of CC BY.
引用
收藏
页码:341 / 349
页数:9
相关论文
共 50 条
  • [41] Salbutamol for analgesia in renal colic: study protocol for a prospective, randomised, placebo-controlled phase II trial (SARC)
    Johnson, Graham
    Tabner, Andrew
    Fakis, Apostolos
    Sherman, Rachelle
    Chester, Victoria
    Bedford, Elizabeth
    Jackson, Richard
    Ratan, Hari
    Mason, Suzanne
    [J]. TRIALS, 2022, 23 (01)
  • [42] Salbutamol for analgesia in renal colic: study protocol for a prospective, randomised, placebo-controlled phase II trial (SARC)
    Graham Johnson
    Andrew Tabner
    Apostolos Fakis
    Rachelle Sherman
    Victoria Chester
    Elizabeth Bedford
    Richard Jackson
    Hari Ratan
    Suzanne Mason
    [J]. Trials, 23
  • [43] Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial
    Sylvie Beumer
    Pauline Hamers
    Alyt Oppewal
    Dederieke Maes-Festen
    [J]. BMC Psychiatry, 21
  • [44] Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial
    Beumer, Sylvie
    Hamers, Pauline
    Oppewal, Alyt
    Maes-Festen, Dederieke
    [J]. BMC PSYCHIATRY, 2021, 21 (01)
  • [45] Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin): study protocol for a randomized controlled trial
    Sam McClinton
    Kathryn Starr
    Ruth Thomas
    Graeme McLennan
    Gladys McPherson
    Alison McDonald
    Thomas Lam
    James N’Dow
    Mary Kilonzo
    Robert Pickard
    Ken Anson
    Jennifer Burr
    [J]. Trials, 15
  • [46] The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomised placebo-controlled trial
    Omar Mubaslat
    Tim Lambert
    [J]. Psychopharmacology, 2020, 237 : 2905 - 2915
  • [47] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter A.
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen L.
    [J]. LANCET, 2011, 378 (9805): : 1779 - 1787
  • [48] Effectiveness of prophylactic antibiotics at placement of dental implants: a pragmatic multicentre placebo-controlled randomised clinical trial
    Esposito, Marco
    Cannizzaro, Gioacchino
    Bozzoli, Paolo
    Checchi, Luigi
    Ferri, Vittorio
    Landriani, Stefano
    Leone, Michele
    Todisco, Marzio
    Torchio, Cinzia
    Testori, Tiziano
    Galli, Fabio
    Felice, Pietro
    [J]. EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY, 2010, 3 (02) : 135 - 143
  • [49] Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study
    Pasquier, Elisabeth
    de Saint-Martin, Luc
    Marhic, Gisele
    Chauleur, Celine
    Bohec, Caroline
    Bretelle, Florence
    Lejeune-Saada, Veronique
    Hannigsberg, Jacob
    Plu-Bureau, Genevieve
    Cogulet, Virginie
    Merviel, Philippe
    Mottier, Dominique
    [J]. BMJ OPEN, 2019, 9 (03):
  • [50] Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial
    Morice, Alyn H.
    McGarvey, Lorcan
    Pavord, Ian D.
    Higgins, Bernard
    Chung, Kian Fan
    Birring, Surinder S.
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (07) : 1864 - 1872